AGP Executive Report
Last update: 12 hours agoCancer Care in Focus: The EMA’s CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv (Padcev) as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC), to be given before radical cystectomy and continued after surgery; the review now goes to the European Commission for marketing authorization in the EU, Iceland, Liechtenstein and Norway, with a final decision expected in Q4 2026. Broader Eligibility: A related CHMP opinion also supports pembrolizumab (or pembrolizumab QLEX) plus Padcev for perioperative use across all resectable MIBC patients eligible for surgery, not just those who are cisplatin-ineligible. Short Bowel Treatment: Zealand Pharma received a positive CHMP opinion for Zeydovio™ (glepaglutide) for adults with short bowel syndrome, reporting that many patients reduced weekly parenteral support and some weaned off entirely after 24 weeks. Local Health Policy Debate: Liechtenstein’s Catholic hereditary prince says he will oppose the newly approved abortion bill after Parliament voted 13–12 for a 12-week time limit. Legal/Access Angle: A Unified Patent Court injunction blocks MGI Tech from selling or supplying CycloneSEQ sequencing systems across multiple markets including Liechtenstein, after an IP dispute with Oxford Nanopore.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27123886-930626510-5eb41dddc2582afbc99f50c263359de127e4fa9c-5500x4000-100x73.jpeg)
